Margaux Nair

Margaux Nair

K&L Gates LLP

Contact  |  View Bio  |  RSS

Latest Publications


ODAC Committee Votes to License Sandoz’s Zarxio®

As noted in our previous client alert, FDA Accepts First Biosimilar Application Filed under Section 351(k) of the Public Health Service Act, Sandoz Inc. (“Sandoz”) filed the first biosimilar application under the Biologics...more

1/9/2015 - Amgen Biosimilars BPCIA FDA Pharmaceutical Prescription Drugs Public Health Service Act Sandoz

Federal Circuit Affirms Dismissal of Sandoz’s BPCIA-Related Declaratory Judgment Action Regarding Enbrel® Patents, but Declines to...

The biologics industry has been eagerly awaiting the Federal Circuit’s ruling on Sandoz Inc.’s (“Sandoz”) appeal from the United States District Court for the Northern District of California’s dismissal of its declaratory...more

12/11/2014 - Appeals Biosimilars BPCIA FDA Jurisdiction Patent Litigation Patents Pharmaceutical Patents Popular Post-Grant Review Sandoz

Declaratory Judgment Action Premature: Decision Suggests “Patent Dance” Mandatory for Biosimilar Applicants

Biosimilar applicants and branded biologics have been wondering how the procedures set forth in the Biologics Price Competition and Innovation Act (“BPCIA”) will be implemented since its enactment in 2010. The lack of...more

12/9/2014 - Allergan v Sandoz Biosimilars BPCIA Patent Litigation Patents Popular Subject Matter Jurisdiction

Next Steps in the Dance: Amgen Files Citizen Petition at FDA Requesting Mandatory Compliance with BPCIA Patent Procedures

Amgen, Inc. (“Amgen”) has brought the discussion of the procedure for biosimilar applications from the courts to the FDA by filing a Citizen Petition (Docket No. FDA-2014-P-1771) on October 29, 2014 (“Petition”) requesting...more

11/12/2014 - Amgen Biologics Biosimilars BPCIA FDA Patent Litigation Patents Prescription Drugs

Left without a Partner: Amgen Sues Sandoz for Refusing to Dance in Accordance with BPCIA Patent Procedures

There has been a lot of curiosity within the biologics industry regarding how the “patent dance” procedures of the Biologics Price Competition and Innovation Act (“BPCIA”) would operate. This interest was piqued in July 2014...more

11/5/2014 - Amgen Biosimilars BPCIA Corporate Counsel FDA Patent Litigation Patents Public Health Service Act Sandoz

Purple is the New Orange: FDA Releases a Purple Book for Biosimilars

On September 9, 2014, the U.S. Food and Drug Administration (“FDA”) published the first edition of the Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or...more

9/16/2014 - Biosimilars BPCIA FDA Pharmaceutical PHSA Popular Purple Book

Abstract Ideas: The Patent Office’s First Take on Alice Corp. v. CLS Bank International

The United States Patent Office periodically issues guidelines for Examiners, often in response to a recent court decision or new statute. These guidelines do not have the force of law, but nevertheless establish the specific...more

7/17/2014 - CLS Bank v Alice Corp Mayo v. Prometheus Patent Applications Patent Examinations Patent Litigation Patent-Eligible Subject Matter Patents Risk Mitigation SCOTUS Software USPTO

U.S. Patent Office Issues Extensive Subject Matter Eligibility Guidelines

The United States Patent Office periodically issues guidance for examiners (“Examiners”), often in response to a recent court decision or new statute. These guidelines do not have the force of law, but nevertheless establish...more

4/15/2014 - Examiners Myriad Patent Applications Patent-Eligible Subject Matter Patents Prometheus USPTO

8 Results
View per page
Page: of 1